MedPath

Clinical study of combinational therapy of AD-4833 with metformin -Phase III double-blind comparative study

Not Applicable
Conditions
Type2 Diabetes
Registration Number
JPRN-UMIN000001110
Lead Sponsor
Takeda Pharmaceutical Company Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
160
Inclusion Criteria

Not provided

Exclusion Criteria

(1)Type 1 diabetes (2)Those who have used different medication for diabetes from metformin-alone (including insulin) period,or have changed the diet therapy and exercise therapy during run-in period

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in HbA1C at the end of the treatment period
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath